Direct impact of COVID-19 by estimating disability-adjusted life years at national level in France in 2020.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
04
2022
accepted:
13
01
2023
entrez:
24
1
2023
pubmed:
25
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
The World Health Organization declared a pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on March 11, 2020. The standardized approach of disability-adjusted life years (DALYs) allows for quantifying the combined impact of morbidity and mortality of diseases and injuries. The main objective of this study was to estimate the direct impact of COVID-19 in France in 2020, using DALYs to combine the population health impact of infection fatalities, acute symptomatic infections and their post-acute consequences, in 28 days (baseline) up to 140 days, following the initial infection. National mortality, COVID-19 screening, and hospital admission data were used to calculate DALYs based on the European Burden of Disease Network consensus disease model. Scenario analyses were performed by varying the number of symptomatic cases and duration of symptoms up to a maximum of 140 days, defining COVID-19 deaths using the underlying, and associated, cause of death. In 2020, the estimated DALYs due to COVID-19 in France were 990 710 (1472 per 100 000), with 99% of burden due to mortality (982 531 years of life lost, YLL) and 1% due to morbidity (8179 years lived with disability, YLD), following the initial infection. The contribution of YLD reached 375%, assuming the duration of 140 days of post-acute consequences of COVID-19. Post-acute consequences contributed to 49% of the total morbidity burden. The contribution of YLD due to acute symptomatic infections among people younger than 70 years was higher (67%) than among people aged 70 years and above (33%). YLL among people aged 70 years and above, contributed to 74% of the total YLL. COVID-19 had a substantial impact on population health in France in 2020. The majority of population health loss was due to mortality. Men had higher population health loss due to COVID-19 than women. Post-acute consequences of COVID-19 had a large contribution to the YLD component of the disease burden, even when we assume the shortest duration of 28 days, long COVID burden is large. Further research is recommended to assess the impact of health inequalities associated with these estimates.
Sections du résumé
BACKGROUND
The World Health Organization declared a pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on March 11, 2020. The standardized approach of disability-adjusted life years (DALYs) allows for quantifying the combined impact of morbidity and mortality of diseases and injuries. The main objective of this study was to estimate the direct impact of COVID-19 in France in 2020, using DALYs to combine the population health impact of infection fatalities, acute symptomatic infections and their post-acute consequences, in 28 days (baseline) up to 140 days, following the initial infection.
METHODS
National mortality, COVID-19 screening, and hospital admission data were used to calculate DALYs based on the European Burden of Disease Network consensus disease model. Scenario analyses were performed by varying the number of symptomatic cases and duration of symptoms up to a maximum of 140 days, defining COVID-19 deaths using the underlying, and associated, cause of death.
RESULTS
In 2020, the estimated DALYs due to COVID-19 in France were 990 710 (1472 per 100 000), with 99% of burden due to mortality (982 531 years of life lost, YLL) and 1% due to morbidity (8179 years lived with disability, YLD), following the initial infection. The contribution of YLD reached 375%, assuming the duration of 140 days of post-acute consequences of COVID-19. Post-acute consequences contributed to 49% of the total morbidity burden. The contribution of YLD due to acute symptomatic infections among people younger than 70 years was higher (67%) than among people aged 70 years and above (33%). YLL among people aged 70 years and above, contributed to 74% of the total YLL.
CONCLUSIONS
COVID-19 had a substantial impact on population health in France in 2020. The majority of population health loss was due to mortality. Men had higher population health loss due to COVID-19 than women. Post-acute consequences of COVID-19 had a large contribution to the YLD component of the disease burden, even when we assume the shortest duration of 28 days, long COVID burden is large. Further research is recommended to assess the impact of health inequalities associated with these estimates.
Identifiants
pubmed: 36693071
doi: 10.1371/journal.pone.0280990
pii: PONE-D-22-11149
pmc: PMC9873186
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0280990Informations de copyright
Copyright: © 2023 Haneef et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: Romana Haneef is the first and corresponding author of this paper, and is the section editor of “health information system” of “Archives of Public Health”. Brecht Devleesschauwer is one of the co-authors of this paper, and is academic editor at PLOS ONE and the guest editor of the article collection on “burden of disease” of “Archives of Public Health”. All other authors declare that they have no competing interests related to the work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
BMC Public Health. 2021 Oct 9;21(1):1827
pubmed: 34627228
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Int J Equity Health. 2021 Sep 26;20(1):214
pubmed: 34565406
Ann Intern Med. 2021 Apr;174(4):576-578
pubmed: 33175566
BMJ. 2020 Apr 27;369:m1557
pubmed: 32341002
Int J Public Health. 2020 Jul;65(6):719-720
pubmed: 32691080
BMJ Open. 2021 Mar 16;11(3):e045343
pubmed: 33727273
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
BMC Public Health. 2014 Nov 21;14:1196
pubmed: 25416547
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Mayo Clin Proc. 2021 Jul;96(7):1782-1791
pubmed: 34218857
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
BMC Public Health. 2022 Jul 9;22(1):1315
pubmed: 35804310
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
Lancet. 2020 Oct 10;396(10257):1068-1069
pubmed: 33007219
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
Dtsch Arztebl Int. 2021 Mar 5;118(9):145-151
pubmed: 33958032
Nature. 2021 Feb;590(7844):134-139
pubmed: 33348340
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Eur J Epidemiol. 2022 Oct;37(10):1035-1047
pubmed: 35951278
Euro Surveill. 2020 Dec;25(50):
pubmed: 33334399
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
J Clin Epidemiol. 2022 Feb;142:54-59
pubmed: 34715312
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Arch Public Health. 2021 Jul 7;79(1):126
pubmed: 34233754
Lancet. 2012 Dec 15;380(9859):2063-6
pubmed: 23245602
Int J Public Health. 2021 Mar 05;66:619011
pubmed: 34744580
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026
BMJ Open Respir Res. 2021 Nov;8(1):
pubmed: 34764200
Int J Public Health. 2022 Jun 02;67:1604699
pubmed: 35719731
Popul Health Metr. 2015 Apr 03;13:10
pubmed: 26778920
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
J Epidemiol Community Health. 2020 Nov;74(11):964-968
pubmed: 32535550
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937